pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,259 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1833Endpoints1420Fierce Biotech742BioSpace733BioPharma Dive541raps241onclive165fda recalls
therapy area
allOncology12628Rare Disease3289Immunology2966Cardiology2832Hematology2240Pulmonology2207Vaccines
  • IQVIA report finds 90% of drugs launched 2016-2020 unlikely to recoup costs
    IQVIA analyzed 825 novel medicines launched in the United States between 1991 and 2020 and found that profitability has sharply declined over time. For drugs launched from 2016 to 2020, a positive…
    BioSpace · 5h agoNegative↗ source
  • Novo’s CagriSema shows over 20% weight loss at low doses in Phase 3 trial
    Novo Nordisk presented new Phase 3 data on its experimental obesity combo CagriSema at ObesityWeek 2026. The low‑dose arm (1 mg and 1.7 mg weekly) achieved average weight reductions of about 21% a…
    BioSpace · 3h agoPositive readoutPositive↗ source
← prev
page 1 of 131
next →
116
fda medwatch112
globenewswire health73
fda press59
1821
Psychiatry & CNS1225
Ophthalmology1110
Endocrinology & Metabolism794
Pain784
Nephrology767
  • Helus Pharma’s Phase 3 trial shows strong depression benefit but safety concerns emerge
    Helus Pharma reported that its deuterated psilocin candidate HLP003 achieved the primary endpoint in a Phase 3 trial for major depressive disorder when added to patients' existing antidepressants.…
    BioSpace · 2h agoNegative readoutNegative↗ source
  • J&J buys Ollin Biosciences for $2.2 billion, taps Blackstone for $750 million Phase 3 eye drug funding
    Johnson & Johnson announced it will acquire Texas‑based ophthalmology biotech Ollin Biosciences, paying $2.2 billion upfront for the company and its late‑stage bispecific antibody targeting retinal…
    BioSpace · 2h agoDealPositive↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5 billion to add blood-cancer assets
    Eli Lilly announced it will acquire privately held Calytrix Bio in a deal valued at up to $1.5 billion in cash. The acquisition is Lilly’s 14th buyout this year and adds a blood-cancer program to…
    BioSpace · 3h agoDealPositive↗ source
  • FDA issues CRL for Summit Therapeutics' ivonescimab, underscoring need for overall survival data
    The FDA sent a complete response letter to Summit Therapeutics, rejecting its biologics license application for ivonescimab, a PD-1xVEGF antibody being tested in EGFR-mutated non-small cell lung ca…
    BioSpace · 3h agoCRLNegative↗ source
  • CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in study
    CG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…
    STAT · 5h agoPositive readoutPositive↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi for redosable DNA medicines
    Seawolf Therapeutics announced a $100 million Series A financing backed by investors including Novartis Venture Fund, Eli Lilly, CRISPR Therapeutics and others. The company also disclosed a multi‑…
    BioSpace · 8h agoDealPositive↗ source
  • Biotech sector rebounds but gains are uneven, with Chinese firms and a large Sofinnova fund leading the surge
    Biotech companies are experiencing a strong year overall, yet investor reactions to positive clinical data remain mixed. Chinese biotech firms are emerging as the top performers, outpacing many pe…
    STAT · 1h agoDealNeutral↗ source
  • Wave Life Sciences reports stronger weight-loss effect of WVE-007 in patients with higher BMI and excess body fat
    Wave Life Sciences presented data at ObesityWeek 2026 from its mid-stage INLIGHT trial of the investigational siRNA drug WVE-007. The analysis of three cohorts showed that participants with higher…
    BioSpace · 3h agoPositive readoutPositive↗ source
  • Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startup
    Versant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…
    STAT · 8h agoDealPositive↗ source
  • AAMC leadership stays vigilant after midterm shift, urges continued congressional support for research
    The Association of American Medical Colleges gathered about 4,100 educators, researchers, clinicians and trainees at its annual meeting in Anaheim, California, a short walk from Disneyland. AAMC C…
    STAT · 8h agoRegulatoryNeutral↗ source
  • Emerging biotech hubs like India could help lower global drug costs by scaling development
    The article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…
    BioSpace · 12h agoNeutral↗ source
  • Biopharma firms showcase non-amyloid Alzheimer’s strategies at CTAD 2026 conference
    Biopharma companies including Biogen, Bristol Myers Squibb and Roche gathered in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, where they presented new data on their…
    BioSpace · 13h agoPositive↗ source
  • Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concerns
    Novartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
    BioSpace · 13h agoNegative readoutNegative↗ source
  • Canadian biotech firms turn to Europe as US political uncertainty creates new market opportunities
    At BIO-Europe in Cologne, Canadian companies said shifting US politics are prompting them to look to European partners. They highlight Canada’s regulatory speed and economic incentives as advantag…
    BioSpace · 3h agoPositive↗ source
  • CDC finds 10% of U.S. adults used GLP-1 drugs in 2025, 20% of them took compounded versions; Russia may seize foreign drug IP
    The Centers for Disease Control and Prevention reported that during July and August 2025 roughly one in ten U.S. adults said they had taken a GLP-1 medication at some point in the prior year. Amon…
    STAT · 3h agoNeutral↗ source
  • Democrats adopt "Medicare for More" as new health-care expansion message
    Democrats in the House have agreed on a new policy slogan, "Medicare for More," signaling a push to broaden health‑care coverage. The phrase is meant to set the agenda apart from the more ambitiou…
    STAT · 4h agoNeutral↗ source
  • BeOne Medicines and Hengrui Lead STAT-WireScreen’s China Biotech Powerhouse 25 Ranking
    STAT and risk‑intelligence platform WireScreen have published a new ranking called China’s Biotech Powerhouse 25, which lists the most valuable publicly traded biotech companies in the country. Th…
    STAT · 8h agoNeutral↗ source
  • STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
    A psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.
    STAT · 5h agoRegulatoryNeutral↗ source
  • Physician burnout persists as hospitals push self-care instead of systemic fixes
    In a new STAT+ column, former ENT surgeon Frances Mei Hardin reflects on the growing crisis of physician burnout and the limited impact of hospital‑mandated wellness programs. Hardin shares a pers…
    STAT · 8h agoNegative↗ source
  • BridgeBio's Morgan Paull and Christine Zhang Named BioSpace 40 Under 40, Emphasize Patient-Centric Model
    BridgeBio has seen two of its young executives, Morgan Paull and Christine Zhang, named to BioSpace’s 2026 40 Under 40 list. Their inclusion highlights the company’s rapid growth and focus on rare-…
    BioSpace · 12h agoPositive↗ source
  • Apple and OpenEvidence Begin Study of Experimental AI Health Chat App
    Apple and OpenEvidence have launched a study centered on an experimental AI-powered health chat application. The pilot allows users to link personal health data to the chatbot, which then provides…
    STAT · 16h agoNeutral↗ source
  • Health-care providers turn to lawsuits over unpaid services as insurance costs squeeze paychecks
    Health-care providers are increasingly filing lawsuits to collect unpaid fees, according to a STAT+ newsletter that cites cases such as an air-ambulance company suing a plumber and a claim involvin…
    STAT · 1h agoNegative↗ source
  • VC John Doerr praises Tom Health AI tool as promising solution for primary care
    Venture capitalist John Doerr highlighted a new artificial-intelligence platform called Tom Health, noting its potential impact on primary-care delivery. Doerr, whose brother's name inspired the c…
    STAT · 7h agoPositive↗ source